ARCH Venture Partners

Rhygaze is focused on developing a novel gene therapy aimed at restoring vision in patients affected by diseases that lead to blindness. The company's innovative technology specifically targets cone cells, which are crucial for light detection but may lose sensitivity due to various conditions. By delivering a light-sensor gene directly to these compromised cone cells, Rhygaze seeks to repair their ability to detect light, thereby offering potential vision restoration solutions for individuals suffering from blindness.

Bit.bio is a synthetic biology company focused on revolutionizing cell therapies by providing consistent and functional human cells for research and medical applications. The company aims to democratize access to these cells through its patented opti-ox™ technology, which safely reprograms human induced pluripotent stem cells (iPSCs) into highly defined, mature cell types. By applying computational principles to biology, Bit.bio seeks to develop a scalable platform that produces consistent batches of human cells. This innovation has the potential to enhance drug discovery and research, moving away from traditional models to work directly with the cells impacted by human diseases. With a team of experts in stem cells, cellular reprogramming, and mathematical modeling, Bit.bio is positioned to support a new generation of cell and tissue therapies, ultimately contributing to advancements in health and medicine.

Vizgen, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in developing advanced spatially resolved transcriptomic profiling tools aimed at enhancing understanding of biological systems related to human health and disease. Founded in 2019, the company has created patented MERFISH technology, which facilitates multiplexed single-molecule imaging to measure RNA species within individual cells, providing insights into gene expression at a subcellular level. This innovative approach allows for single-cell gene expression profiling in intact tissue slices, enabling researchers to explore various applications in fields such as oncology, immunology, neuroscience, infectious diseases, developmental biology, and regenerative medicine. Through its cutting-edge technology, Vizgen seeks to unlock new dimensions of biological research and improve methods for studying complex diseases.

City Therapeutics is a biopharmaceutical company specializing in the development of next-generation small-interfering RNAs (siRNAs) to enhance RNA interference (RNAi) therapies. The company's pipeline comprises innovative RNAi therapeutics targeting diverse disease indications. City Therapeutics aims to improve and expand RNAi technology to achieve better patient outcomes, led by a team of experienced scientists and industry professionals committed to advancing the field of RNA interference.

Egenesis Inc. is a biotechnology company focused on gene editing and genome engineering to create human transplantable organs, tissues, and cells. Established in 2015 and headquartered in Cambridge, Massachusetts, with an additional office in New York City, Egenesis aims to address the global organ shortage by developing solid organs and therapeutic cell transplantation solutions for various diseases. The company utilizes a gene editing platform that incorporates techniques such as single-cell cloning and somatic cell nuclear transfer, which are essential for creating human-compatible organ tissues and cells. Egenesis is particularly engaged in advancing programs related to kidney and islet cell transplantation, striving to provide alternative treatment options for patients with life-threatening conditions.

Moleculent is a biotechnology company focused on advancing human health through the development of technology-enabled products that harness insights from the molecular foundations of human biology. By decoding human biology, the company aims to enhance therapies and diagnostics, thereby improving healthcare outcomes. Moleculent anticipates significant advancements in the understanding of molecular biology over the next decade, which will facilitate the creation of innovative treatments and diagnostic tools. Their mission centers on providing healthcare professionals with access to molecular science-based solutions that address various health challenges.

Slingshot Biosciences, Inc. is a manufacturer of biological products based in Emeryville, California, founded in 2012. The company focuses on developing next-generation synthetic cells aimed at enhancing diagnostics and therapeutics. By creating engineered synthetic cells, Slingshot Biosciences addresses challenges in drug research, particularly in measuring and standardizing cell analysis. Their innovations enable researchers to conduct advanced diagnostics without the limitations of cold-chain logistics, making their solutions more accessible. Additionally, the company is committed to developing products that target neglected and rare diseases, providing elegant and cost-effective solutions for common issues in research and development.

Moonwalk Biosciences is a genomic medicine startup focused on developing precision epigenetic therapeutics. The company is creating a profiling and engineering technology platform that leverages advanced artificial intelligence to deliver an in-depth understanding of the epigenome in both health and disease. This innovative approach allows healthcare providers to explore new avenues for therapy discovery and facilitates the reprogramming of cells to restore their healthy state. By integrating AI-driven insights, Moonwalk Biosciences aims to transform the landscape of therapeutic development and improve patient outcomes.

Tome Biosciences is a biotechnology company specializing in programmable gene insertion technology. Utilizing CRISPR, the company develops methods to insert genetic sequences of any size at various locations within any genome. This innovative approach aims to enhance the ability to detect and eliminate deoxyribonucleic acid from similar bacteriophages during infections. By advancing cell and genome engineering, Tome Biosciences seeks to provide effective therapeutic solutions for patients, paving the way for significant advancements in genetic medicine.

Paratus Sciences is a biotechnology company focused on enhancing human health and health security through the study of bat biology. By exploring the unique aspects of the bat genome, the company aims to identify and develop therapeutics for a variety of diseases. Paratus Sciences seeks to unlock the secrets of bat biology to facilitate innovative treatments, ultimately helping patients combat the health challenges they encounter.

Aera Therapeutics is a biotechnology company focused on enhancing the delivery of genetic medicines through its proprietary protein nanoparticle (PNP) platform. This innovative platform utilizes endogenous human proteins to create capsid-like structures that can effectively package and transfer nucleic acid cargo. By addressing the limitations of current delivery technologies, Aera aims to extend the application of genetic medicines across various tissues and disease areas, ultimately benefiting a wider patient population. In addition to its PNP platform, Aera has developed a therapeutic enzyme platform that features novel, compact, and programmable gene-editing enzymes, further advancing its mission to transform the field of genetic medicine.

Aera Therapeutics is a biotechnology company focused on enhancing the delivery of genetic medicines through its proprietary protein nanoparticle (PNP) platform. This innovative platform utilizes endogenous human proteins to create capsid-like structures that can effectively package and transfer nucleic acid cargo. By addressing the limitations of current delivery technologies, Aera aims to extend the application of genetic medicines across various tissues and disease areas, ultimately benefiting a wider patient population. In addition to its PNP platform, Aera has developed a therapeutic enzyme platform that features novel, compact, and programmable gene-editing enzymes, further advancing its mission to transform the field of genetic medicine.

Slingshot Biosciences, Inc. is a manufacturer of biological products based in Emeryville, California, founded in 2012. The company focuses on developing next-generation synthetic cells aimed at enhancing diagnostics and therapeutics. By creating engineered synthetic cells, Slingshot Biosciences addresses challenges in drug research, particularly in measuring and standardizing cell analysis. Their innovations enable researchers to conduct advanced diagnostics without the limitations of cold-chain logistics, making their solutions more accessible. Additionally, the company is committed to developing products that target neglected and rare diseases, providing elegant and cost-effective solutions for common issues in research and development.

SonoThera is a biotechnology company focused on developing non-viral genetic therapies using ultrasound technology. The company aims to create genetic medicines that address the root causes of human diseases, particularly for conditions that currently have limited or no effective treatments. By leveraging ultrasound-guided nonviral gene therapy, SonoThera seeks to enhance treatment options and improve health outcomes for millions of patients.

Vizgen, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in developing advanced spatially resolved transcriptomic profiling tools aimed at enhancing understanding of biological systems related to human health and disease. Founded in 2019, the company has created patented MERFISH technology, which facilitates multiplexed single-molecule imaging to measure RNA species within individual cells, providing insights into gene expression at a subcellular level. This innovative approach allows for single-cell gene expression profiling in intact tissue slices, enabling researchers to explore various applications in fields such as oncology, immunology, neuroscience, infectious diseases, developmental biology, and regenerative medicine. Through its cutting-edge technology, Vizgen seeks to unlock new dimensions of biological research and improve methods for studying complex diseases.

LifeMine Therapeutics, Inc. is a biotechnology company focused on discovering new drug modalities from eukaryotic microbes, particularly fungi. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in New York, the company employs an integrated platform that combines genomics, artificial intelligence, and synthetic biology. This innovative Avatar-Rx platform utilizes high-throughput microbiology, data science, machine learning, genome engineering, and automation to explore the fungal biosphere for novel genetically encoded molecules with specific biological functions. By integrating chemoinformatic-assisted drug optimization and advanced chemical synthesis with biotransformation, LifeMine Therapeutics aims to advance a pipeline of new medicines into development.

Singleron Biotechnologies Ltd. is a molecular diagnostic company specializing in single cell sequencing solutions. Founded in 2018 and based in Nanjing, China, with additional offices and laboratories in Suzhou, the United States, and Germany, the firm develops a range of innovative products, including the Singleron Matrix automated instrument for high-density microwell processing and GEXSCOPE single cell RNA sequencing kits. The company also offers a microfluidic chip for cell partitioning, magnetic beads for cell barcoding, and tools for data analysis such as CeleScope and SynEcoSys, which facilitate the interpretation of single cell sequencing data. Singleron provides services in single cell RNA sequencing, single nucleus RNA sequencing, and bioinformatics analysis, aiming to advance clinical diagnosis, drug development, and health management. The company collaborates with research institutes, hospitals, and pharmaceutical firms primarily in China and the United States, leveraging its exclusive IP license from Yale University to enhance its innovative capabilities in single cell analysis.

ROME Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for cancer and autoimmune diseases. Established in 2019, the company utilizes the repeatome—a previously overlooked segment of genetic material—to create novel treatment options. By identifying multiple drug targets and advancing several discovery programs, ROME Therapeutics aims to tap into this unexplored area of biology. The organization has assembled a team of experts in oncology, immunology, virology, and machine learning to lead its research and development efforts, which are designed to provide healthcare professionals with effective new treatments for patients suffering from these conditions.

Slingshot Biosciences, Inc. is a manufacturer of biological products based in Emeryville, California, founded in 2012. The company focuses on developing next-generation synthetic cells aimed at enhancing diagnostics and therapeutics. By creating engineered synthetic cells, Slingshot Biosciences addresses challenges in drug research, particularly in measuring and standardizing cell analysis. Their innovations enable researchers to conduct advanced diagnostics without the limitations of cold-chain logistics, making their solutions more accessible. Additionally, the company is committed to developing products that target neglected and rare diseases, providing elegant and cost-effective solutions for common issues in research and development.

Interline Therapeutics is a drug discovery platform based in South San Francisco, California, founded in 2020 by Zach Sweeney. The company specializes in mapping and correcting dysfunctional protein communities to elucidate the molecular mechanisms of disease. By utilizing advancements in genomics, proteomics, structural biology, and computational chemistry, Interline aims to develop a precision medicine approach that focuses on three key areas: genomics, communities, and modulators. This innovative methodology enables the identification of new medicines targeting genetically validated signaling pathways and ensures that drug candidates effectively address dysfunctional disease networks. Through collaborations with leading academic institutions, Interline Therapeutics strives to enhance drug discovery and improve therapeutic outcomes.

Jaguar Gene Therapy is a clinical-stage biotechnology company focused on advancing gene therapy solutions for patients with severe genetic diseases. The company aims to address significant unmet medical needs by developing therapies that target nonworking or absent genes, introducing healthy copies of these genes to restore their function. By accelerating the process of bringing innovative gene therapies from research to clinical application, Jaguar Gene Therapy seeks to improve patient outcomes and enhance the overall standard of care for those affected by genetic disorders.

Vizgen, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in developing advanced spatially resolved transcriptomic profiling tools aimed at enhancing understanding of biological systems related to human health and disease. Founded in 2019, the company has created patented MERFISH technology, which facilitates multiplexed single-molecule imaging to measure RNA species within individual cells, providing insights into gene expression at a subcellular level. This innovative approach allows for single-cell gene expression profiling in intact tissue slices, enabling researchers to explore various applications in fields such as oncology, immunology, neuroscience, infectious diseases, developmental biology, and regenerative medicine. Through its cutting-edge technology, Vizgen seeks to unlock new dimensions of biological research and improve methods for studying complex diseases.

Interline Therapeutics is a drug discovery platform based in South San Francisco, California, founded in 2020 by Zach Sweeney. The company specializes in mapping and correcting dysfunctional protein communities to elucidate the molecular mechanisms of disease. By utilizing advancements in genomics, proteomics, structural biology, and computational chemistry, Interline aims to develop a precision medicine approach that focuses on three key areas: genomics, communities, and modulators. This innovative methodology enables the identification of new medicines targeting genetically validated signaling pathways and ensures that drug candidates effectively address dysfunctional disease networks. Through collaborations with leading academic institutions, Interline Therapeutics strives to enhance drug discovery and improve therapeutic outcomes.

Excision BioTherapeutics Inc. is a life science company based in Philadelphia, Pennsylvania, established in 2015. The company specializes in developing gene editing therapeutics aimed at treating life-threatening diseases caused by neurotropic viruses. Utilizing CRISPR-based technology, Excision BioTherapeutics focuses on creating advanced gene-editing medicines that can eradicate or disrupt viral genes in human patients. The company is committed to advancing these therapeutics to ensure they are safe and effective, with the goal of significantly improving the lives of individuals affected by viral infections worldwide.

LifeMine Therapeutics, Inc. is a biotechnology company focused on discovering new drug modalities from eukaryotic microbes, particularly fungi. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in New York, the company employs an integrated platform that combines genomics, artificial intelligence, and synthetic biology. This innovative Avatar-Rx platform utilizes high-throughput microbiology, data science, machine learning, genome engineering, and automation to explore the fungal biosphere for novel genetically encoded molecules with specific biological functions. By integrating chemoinformatic-assisted drug optimization and advanced chemical synthesis with biotransformation, LifeMine Therapeutics aims to advance a pipeline of new medicines into development.

Altos Labs is a biotechnology company dedicated to cellular rejuvenation programming aimed at restoring cell health and resilience. The organization seeks to develop innovative approaches to medicine that can reverse diseases, injuries, and disabilities. By uniting a community of prominent scientists, clinicians, and industry leaders, Altos Labs fosters collaboration across its operations in the San Francisco Bay Area, San Diego, and Cambridge, UK, while also engaging in significant partnerships in Japan. Through its research and initiatives, the company aspires to transform the landscape of medical treatment.

Encodia, Inc., founded in 2015 and headquartered in San Diego, California, specializes in proteomics research and the development of innovative protein analysis technology. The company offers a platform that utilizes reverse-translation technology to convert peptide sequence information into DNA libraries, facilitating scalable and efficient protein sequencing. This capability enables researchers to analyze protein samples comprehensively, thereby advancing the field of personalized medicine. By democratizing access to detailed information on cellular processes, Encodia aims to accelerate the discovery of novel approaches to addressing challenging diseases.

Locanabio, Inc. is a biotechnology company based in San Diego, California, founded in 2016. It specializes in developing RNA-targeted gene therapies aimed at treating a range of underserved diseases, particularly in the areas of neuromuscular, neurodegenerative, and retinal conditions. The company's innovative platform focuses on modifying disease-causing RNA, allowing for the identification and correction of specific RNA sequences associated with rare genetic disorders. This approach distinguishes Locanabio's therapies from traditional DNA-targeted methods, offering a unique solution for patients with severe and challenging health issues. The company, which rebranded from Locana, Inc. in July 2020, is dedicated to advancing therapeutic candidates that address significant medical needs.

Singleron Biotechnologies Ltd. is a molecular diagnostic company specializing in single cell sequencing solutions. Founded in 2018 and based in Nanjing, China, with additional offices and laboratories in Suzhou, the United States, and Germany, the firm develops a range of innovative products, including the Singleron Matrix automated instrument for high-density microwell processing and GEXSCOPE single cell RNA sequencing kits. The company also offers a microfluidic chip for cell partitioning, magnetic beads for cell barcoding, and tools for data analysis such as CeleScope and SynEcoSys, which facilitate the interpretation of single cell sequencing data. Singleron provides services in single cell RNA sequencing, single nucleus RNA sequencing, and bioinformatics analysis, aiming to advance clinical diagnosis, drug development, and health management. The company collaborates with research institutes, hospitals, and pharmaceutical firms primarily in China and the United States, leveraging its exclusive IP license from Yale University to enhance its innovative capabilities in single cell analysis.

Sana Biotechnology, Inc. is a biotechnology company focused on developing engineered cells as therapies to treat a wide range of diseases. Established in 2018 and headquartered in Seattle, Washington, with additional offices in South San Francisco and Cambridge, the company utilizes advanced scientific techniques to reprogram cells or replace damaged cells and tissues. This innovative approach aims to create a new class of medicines that address unmet treatment needs across various therapeutic areas, including oncology, diabetes, autoimmune disorders, and central nervous system conditions. Sana's pipeline includes several product candidates designed to provide meaningful medical solutions and transform disease treatment methodologies.

Bit.bio is a synthetic biology company focused on revolutionizing cell therapies by providing consistent and functional human cells for research and medical applications. The company aims to democratize access to these cells through its patented opti-ox™ technology, which safely reprograms human induced pluripotent stem cells (iPSCs) into highly defined, mature cell types. By applying computational principles to biology, Bit.bio seeks to develop a scalable platform that produces consistent batches of human cells. This innovation has the potential to enhance drug discovery and research, moving away from traditional models to work directly with the cells impacted by human diseases. With a team of experts in stem cells, cellular reprogramming, and mathematical modeling, Bit.bio is positioned to support a new generation of cell and tissue therapies, ultimately contributing to advancements in health and medicine.

Verve Therapeutics, Inc. is a genetic medicines company focused on innovative treatments for cardiovascular disease through gene editing. Founded in 2018 and based in Cambridge, Massachusetts, with a research facility in Philadelphia, the company aims to shift the management of cardiovascular conditions from chronic treatments to single-course gene editing therapies. Its initial programs concentrate on the PCSK9 and ANGPTL3 genes, which are known to significantly impact blood lipid levels, a major factor in cardiovascular disease. Verve Therapeutics collaborates with partners such as Beam Therapeutics and Verily to enhance its gene editing delivery technologies. The company is staffed by a team of experts in cardiovascular medicine, human genetics, and drug development, positioning itself to address the challenges of cardiovascular health effectively.

ROME Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for cancer and autoimmune diseases. Established in 2019, the company utilizes the repeatome—a previously overlooked segment of genetic material—to create novel treatment options. By identifying multiple drug targets and advancing several discovery programs, ROME Therapeutics aims to tap into this unexplored area of biology. The organization has assembled a team of experts in oncology, immunology, virology, and machine learning to lead its research and development efforts, which are designed to provide healthcare professionals with effective new treatments for patients suffering from these conditions.

Aspen Neuroscience, Inc. is a biotechnology company focused on developing induced pluripotent stem cells (iPSCs) to create patient-specific therapies for neurological conditions, particularly Parkinson's disease. Founded in 2018 and based in San Diego, California, the company is advancing its pipeline of products, which includes ANPD001, an autologous neuron replacement therapy for sporadic Parkinson's disease, and ANPD002, a gene-edited autologous neuron replacement therapy targeting familial forms of the disease. Aspen Neuroscience employs innovative genomic approaches in conjunction with stem cell biology to address diseases with significant unmet medical needs, aiming to provide restorative cell therapies that can modify the progression of Parkinson's disease and potentially extend to other affected organs.

Vizgen, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in developing advanced spatially resolved transcriptomic profiling tools aimed at enhancing understanding of biological systems related to human health and disease. Founded in 2019, the company has created patented MERFISH technology, which facilitates multiplexed single-molecule imaging to measure RNA species within individual cells, providing insights into gene expression at a subcellular level. This innovative approach allows for single-cell gene expression profiling in intact tissue slices, enabling researchers to explore various applications in fields such as oncology, immunology, neuroscience, infectious diseases, developmental biology, and regenerative medicine. Through its cutting-edge technology, Vizgen seeks to unlock new dimensions of biological research and improve methods for studying complex diseases.

Omniome, Inc. is a biotechnology company based in San Diego, California, focused on developing a DNA sequencing platform that aims to deliver high accuracy in clinical sequencing. Founded in 2013, the company utilizes its proprietary Sequencing By Binding technology, which enhances nucleotide and DNA matching by harnessing the natural capabilities of polymerase. This innovative approach allows researchers to obtain accurate and rapid sequencing results at a lower cost, with the potential to significantly advance cancer diagnostics. Omniome is supported by prominent life sciences venture investors and is committed to becoming a trusted leader in the field of DNA sequencing.

Aspen Neuroscience, Inc. is a biotechnology company focused on developing induced pluripotent stem cells (iPSCs) to create patient-specific therapies for neurological conditions, particularly Parkinson's disease. Founded in 2018 and based in San Diego, California, the company is advancing its pipeline of products, which includes ANPD001, an autologous neuron replacement therapy for sporadic Parkinson's disease, and ANPD002, a gene-edited autologous neuron replacement therapy targeting familial forms of the disease. Aspen Neuroscience employs innovative genomic approaches in conjunction with stem cell biology to address diseases with significant unmet medical needs, aiming to provide restorative cell therapies that can modify the progression of Parkinson's disease and potentially extend to other affected organs.

Egenesis Inc. is a biotechnology company focused on gene editing and genome engineering to create human transplantable organs, tissues, and cells. Established in 2015 and headquartered in Cambridge, Massachusetts, with an additional office in New York City, Egenesis aims to address the global organ shortage by developing solid organs and therapeutic cell transplantation solutions for various diseases. The company utilizes a gene editing platform that incorporates techniques such as single-cell cloning and somatic cell nuclear transfer, which are essential for creating human-compatible organ tissues and cells. Egenesis is particularly engaged in advancing programs related to kidney and islet cell transplantation, striving to provide alternative treatment options for patients with life-threatening conditions.

Prime Medicine is a biotechnology company focused on developing genetic therapies using its proprietary Prime Editing technology. This next-generation gene editing method allows for precise "search and replace" modifications in the genome, aiming to restore normal genetic function and address the underlying causes of various diseases. By targeting a broad spectrum of conditions with significant unmet medical needs, Prime Medicine seeks to revolutionize the field of genetic medicine through effective and efficient therapeutic solutions.

Encoded Therapeutics, Inc. is a biotechnology company that specializes in precision gene therapies aimed at treating a wide array of severe genetic disorders. Utilizing a unique platform, Encoded identifies sequences within the human genome that regulate gene expression through advanced screening and computational techniques. The company's therapy pipeline targets both genetic and acquired disorders across various disease pathways, including neurocircuitry, liver and metabolic disorders, neurodegeneration, and cardiovascular diseases. Founded in 2014 and based in South San Francisco, California, Encoded Therapeutics is focused on developing innovative solutions that enable medical practitioners to improve patient outcomes and enhance quality of life.

Locanabio, Inc. is a biotechnology company based in San Diego, California, founded in 2016. It specializes in developing RNA-targeted gene therapies aimed at treating a range of underserved diseases, particularly in the areas of neuromuscular, neurodegenerative, and retinal conditions. The company's innovative platform focuses on modifying disease-causing RNA, allowing for the identification and correction of specific RNA sequences associated with rare genetic disorders. This approach distinguishes Locanabio's therapies from traditional DNA-targeted methods, offering a unique solution for patients with severe and challenging health issues. The company, which rebranded from Locana, Inc. in July 2020, is dedicated to advancing therapeutic candidates that address significant medical needs.

LunaDNA is a community-owned platform that facilitates the sharing of health and DNA data for medical research. Founded by the creators of Illumina, a leader in DNA sequencing, LunaDNA addresses the issue of siloed genomic data by providing individuals with a compelling incentive to share their health information. Participants are rewarded with shares in the database, allowing them to benefit from the profits generated by medical research and discoveries. This model not only empowers users to contribute their health records, genomic data, and personal health experiences but also fosters a sense of community ownership. As researchers pay to access the data for their studies, the proceeds are distributed back to the community, akin to dividends. By prioritizing privacy and trust, LunaDNA aims to increase participation in genomic research while facilitating advancements in healthcare that can ultimately save lives.

LunaPBC, Inc. is a Public Benefit Corporation based in San Diego, California, that develops a community-owned platform for genomic and medical research. The company's primary offering, LunaDNA, serves as a knowledge database where individuals can share their health and DNA data to contribute to health research and drive medical discoveries. This platform is designed to benefit both non-profit and for-profit health research projects, facilitating collaboration among pharmaceutical, insurance, and healthcare IT companies. In addition to advancing medical research, LunaPBC allows its members to share in the financial benefits derived from medical breakthroughs, promoting a model of shared community ownership.

Verve Therapeutics, Inc. is a genetic medicines company focused on innovative treatments for cardiovascular disease through gene editing. Founded in 2018 and based in Cambridge, Massachusetts, with a research facility in Philadelphia, the company aims to shift the management of cardiovascular conditions from chronic treatments to single-course gene editing therapies. Its initial programs concentrate on the PCSK9 and ANGPTL3 genes, which are known to significantly impact blood lipid levels, a major factor in cardiovascular disease. Verve Therapeutics collaborates with partners such as Beam Therapeutics and Verily to enhance its gene editing delivery technologies. The company is staffed by a team of experts in cardiovascular medicine, human genetics, and drug development, positioning itself to address the challenges of cardiovascular health effectively.

Beam Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, specializing in the development of precision genetic medicines utilizing its innovative base editing technology. Founded in 2017, the company aims to provide lifelong cures for patients suffering from serious diseases by targeting specific bases in the genome without inducing double-stranded breaks in DNA. Beam Therapeutics is actively developing therapies for a range of conditions, including sickle cell disease, beta-thalassemia, pediatric T-cell acute lymphoblastic leukemia, pediatric acute myeloid leukemia, alpha-1 antitrypsin deficiency, glycogen storage disorder type 1A, as well as ocular and central nervous system disorders. The company’s diverse pipeline includes several programs such as BEAM-101, BEAM-201, BEAM-301, BEAM-302, and ESCAPE, reflecting its commitment to advancing gene correction, gene modification, gene activation, gene silencing, and multiplex editing technologies.

Maze Therapeutics is a biotechnology company based in South San Francisco, California, focused on developing innovative medicines that leverage the effects of rare genetic variants to address unmet medical needs. Founded in 2017 and originally known as Modulus Therapeutics, the company utilizes its proprietary Compass platform to identify genetic variants linked to diseases and map them to the biological pathways that drive these conditions in specific patient populations. By integrating large-scale human genetics data and functional genomics with various drug discovery methods, Maze Therapeutics aims to reveal modifier genes that offer protective benefits. This approach enhances the understanding of target biology and informs the development of novel therapies, ultimately enabling pharmaceutical companies to create effective treatments.

Sana Biotechnology, Inc. is a biotechnology company focused on developing engineered cells as therapies to treat a wide range of diseases. Established in 2018 and headquartered in Seattle, Washington, with additional offices in South San Francisco and Cambridge, the company utilizes advanced scientific techniques to reprogram cells or replace damaged cells and tissues. This innovative approach aims to create a new class of medicines that address unmet treatment needs across various therapeutic areas, including oncology, diabetes, autoimmune disorders, and central nervous system conditions. Sana's pipeline includes several product candidates designed to provide meaningful medical solutions and transform disease treatment methodologies.

Geneception is a company focused on the development of breakthrough in gene and cell therapies that are fully-integrated.

Lyell Immunopharma Inc is a clinical-stage cell therapy company focused on developing innovative treatments for patients with solid tumors through T cell reprogramming. The company aims to overcome significant challenges in adoptive T cell therapy, specifically T cell exhaustion and loss of durable stemness, which impede effective and lasting responses in cancer treatment. Utilizing its proprietary platforms, Gen-R and Epi-R, Lyell is working to enhance the proliferative capacity, self-renewal, and differentiation abilities of T cells. The company's product pipeline includes several candidates, such as LYL797, LYL119, and LYL845, all designed to deliver improved and potentially curative outcomes for patients suffering from solid tumors.

KSQ Therapeutics, Inc., founded in 2015 and based in Cambridge, Massachusetts, specializes in precision functional genomics to discover innovative drug therapies. The company employs a novel approach to research and development that emphasizes de-risking prior to the creation of therapeutic candidates. Utilizing its proprietary CRISPRomics™ drug discovery engine, KSQ Therapeutics has mapped the functions of human genes across various diseases, enhancing its understanding of disease biology. This comprehensive insight enables the identification and validation of high-confidence, patient-specific drug targets. As a result, the company is focused on developing medicines that have significant potential to improve patient outcomes and has established a pipeline of preclinical discovery programs.

Omniome, Inc. is a biotechnology company based in San Diego, California, focused on developing a DNA sequencing platform that aims to deliver high accuracy in clinical sequencing. Founded in 2013, the company utilizes its proprietary Sequencing By Binding technology, which enhances nucleotide and DNA matching by harnessing the natural capabilities of polymerase. This innovative approach allows researchers to obtain accurate and rapid sequencing results at a lower cost, with the potential to significantly advance cancer diagnostics. Omniome is supported by prominent life sciences venture investors and is committed to becoming a trusted leader in the field of DNA sequencing.

Qihan Biotech is a biomedical company specializing in genetic technology with a focus on xenotransplantation. The company aims to address the critical shortage of organ donors by utilizing advanced gene editing techniques to develop safe and effective cells, tissues, and organs for human transplantation. Their mission is to eliminate the waiting period associated with organ transplants, providing patients with access to life-saving organs. By harnessing cutting-edge genetic editing technology, Qihan Biotech seeks to create viable organs that can be transplanted into humans, thereby contributing to a solution for the global organ donor crisis.

AgBiome, LLC is a biotechnology company based in Durham, North Carolina, that focuses on developing biological products to address significant challenges in agriculture, particularly soil-borne diseases affecting greenhouse and major row crops. Utilizing advanced genomics and screening technologies, AgBiome identifies plant-associated microbes that can enhance plant health, improve pest resistance, and increase crop yields. The company operates a state-of-the-art laboratory and greenhouse facility and collaborates with prominent agricultural firms to expedite its research and product development. AgBiome's offerings include fungicides that protect crops from various diseases and a platform for capturing and screening diverse microbes for agricultural applications. Established in 2012, AgBiome aims to provide sustainable solutions that support global food production and address critical agricultural issues such as insect and nematode control.

Beam Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, specializing in the development of precision genetic medicines utilizing its innovative base editing technology. Founded in 2017, the company aims to provide lifelong cures for patients suffering from serious diseases by targeting specific bases in the genome without inducing double-stranded breaks in DNA. Beam Therapeutics is actively developing therapies for a range of conditions, including sickle cell disease, beta-thalassemia, pediatric T-cell acute lymphoblastic leukemia, pediatric acute myeloid leukemia, alpha-1 antitrypsin deficiency, glycogen storage disorder type 1A, as well as ocular and central nervous system disorders. The company’s diverse pipeline includes several programs such as BEAM-101, BEAM-201, BEAM-301, BEAM-302, and ESCAPE, reflecting its commitment to advancing gene correction, gene modification, gene activation, gene silencing, and multiplex editing technologies.

LunaDNA is a community-owned platform that facilitates the sharing of health and DNA data for medical research. Founded by the creators of Illumina, a leader in DNA sequencing, LunaDNA addresses the issue of siloed genomic data by providing individuals with a compelling incentive to share their health information. Participants are rewarded with shares in the database, allowing them to benefit from the profits generated by medical research and discoveries. This model not only empowers users to contribute their health records, genomic data, and personal health experiences but also fosters a sense of community ownership. As researchers pay to access the data for their studies, the proceeds are distributed back to the community, akin to dividends. By prioritizing privacy and trust, LunaDNA aims to increase participation in genomic research while facilitating advancements in healthcare that can ultimately save lives.

Biopalette is a company focused on developing advanced gene-editing techniques aimed at creating innovative therapies. The business operates a platform that combines genome editing and microbiome engineering, allowing for the cultivation of bacteria through targeted genome modifications. This technology enables scientists to explore and test various applications in gene editing, specifically tailored to different types of cells. Biopalette's approach positions it at the intersection of genetics and microbiome science, facilitating breakthroughs in therapeutic development.

Codiak BioSciences is a clinical-stage biopharmaceutical company dedicated to developing exosome-based therapeutics, a novel class of medicines with the potential to address various diseases with significant unmet medical needs. The company employs its proprietary engEx Platform, which allows for the engineering and manufacturing of exosomes, leveraging their natural role as intercellular messengers. Codiak's pipeline includes product candidates such as exoSTING and exoIL-12, targeting diverse therapeutic areas including oncology, neuro-oncology, neurology, neuromuscular diseases, and infectious diseases. Additionally, the company collaborates with the Ragon Institute to explore the potential of its exoVACC platform for vaccines against SARS-CoV-2 and HIV. Founded in 2015 and headquartered in Cambridge, Massachusetts, Codiak aims to transform therapeutic approaches by harnessing the unique properties of exosomes.

AnchorDx, also known as Guangzhou Baseline Medical, specializes in high-throughput sequencing technologies and molecular liquid biopsies, offering non-invasive access to genetic information. The company focuses on precision medicine and aims to be a leading global provider of medical solutions by leveraging its expertise in cancer genomics, genetics, and bioinformatics. With a core team possessing over 20 years of industry experience, AnchorDx collaborates with various downstream enterprises, hospitals, and research institutions to create an integrated industrial chain that facilitates the transformation of academic research into clinical products. The company is committed to developing independent intellectual property rights and competitive clinical testing products, thereby providing accurate and comprehensive services to patients, doctors, and medical institutions.

KSQ Therapeutics, Inc., founded in 2015 and based in Cambridge, Massachusetts, specializes in precision functional genomics to discover innovative drug therapies. The company employs a novel approach to research and development that emphasizes de-risking prior to the creation of therapeutic candidates. Utilizing its proprietary CRISPRomics™ drug discovery engine, KSQ Therapeutics has mapped the functions of human genes across various diseases, enhancing its understanding of disease biology. This comprehensive insight enables the identification and validation of high-confidence, patient-specific drug targets. As a result, the company is focused on developing medicines that have significant potential to improve patient outcomes and has established a pipeline of preclinical discovery programs.

LifeMine Therapeutics, Inc. is a biotechnology company focused on discovering new drug modalities from eukaryotic microbes, particularly fungi. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in New York, the company employs an integrated platform that combines genomics, artificial intelligence, and synthetic biology. This innovative Avatar-Rx platform utilizes high-throughput microbiology, data science, machine learning, genome engineering, and automation to explore the fungal biosphere for novel genetically encoded molecules with specific biological functions. By integrating chemoinformatic-assisted drug optimization and advanced chemical synthesis with biotransformation, LifeMine Therapeutics aims to advance a pipeline of new medicines into development.

Arbor Biotechnologies, Inc., founded in 2016 and headquartered in Cambridge, Massachusetts, operates as a bio-discovery company in the biotechnology sector. The company focuses on developing genomic tools that enhance human health and sustainability. Utilizing a combination of artificial intelligence, genome sequencing, gene synthesis, and high-throughput screening, Arbor's platform accelerates the discovery of proteins and facilitates human diagnostic development. The technology aggregates genomic sequence data through AI and machine learning, enabling drug developers to replace entire genes and precisely correct mutations. This approach aims to streamline the development of curative treatments for previously incurable genetic diseases, ultimately improving the lives of patients affected by such conditions.

Biopalette is a company focused on developing advanced gene-editing techniques aimed at creating innovative therapies. The business operates a platform that combines genome editing and microbiome engineering, allowing for the cultivation of bacteria through targeted genome modifications. This technology enables scientists to explore and test various applications in gene editing, specifically tailored to different types of cells. Biopalette's approach positions it at the intersection of genetics and microbiome science, facilitating breakthroughs in therapeutic development.

Egenesis Inc. is a biotechnology company focused on gene editing and genome engineering to create human transplantable organs, tissues, and cells. Established in 2015 and headquartered in Cambridge, Massachusetts, with an additional office in New York City, Egenesis aims to address the global organ shortage by developing solid organs and therapeutic cell transplantation solutions for various diseases. The company utilizes a gene editing platform that incorporates techniques such as single-cell cloning and somatic cell nuclear transfer, which are essential for creating human-compatible organ tissues and cells. Egenesis is particularly engaged in advancing programs related to kidney and islet cell transplantation, striving to provide alternative treatment options for patients with life-threatening conditions.

ApoGen Biotechnologies, Inc., founded in 2014 and located in Seattle, Washington, is dedicated to developing innovative therapeutics aimed at addressing the challenges of cancer treatment, particularly the issue of drug resistance. The company focuses on targeting the key drivers of genomic mutations in cancer cells, which are central to tumor evolution and the development of resistance to existing therapies. By addressing the chronic mutations in cancer genomes, ApoGen aims to improve treatment efficacy, reduce cancer recurrence and metastasis, and enhance overall patient survival. The company's approach represents a shift from traditional therapies, providing new hope in the ongoing battle against cancer.

Genomics Medicine Ireland is a life sciences company focused on conducting extensive research studies throughout Ireland to explore the connections between the human genome, health, and disease. By analyzing genetic information, the company aims to deepen the understanding of how genetics influences various health outcomes and disease susceptibility. Through its research initiatives, Genomics Medicine Ireland seeks to contribute valuable insights that could inform future medical practices and enhance healthcare delivery.

Denali Therapeutics is a biopharmaceutical company dedicated to discovering and developing therapies for neurodegenerative diseases such as Alzheimer's, Parkinson's disease, and amyotrophic lateral sclerosis (ALS). The company is advancing several therapeutic candidates, including LRRK2 inhibitors like DNL201 and DNL151 for Parkinson's disease, and DNL747, a RIPK1 inhibitor targeting Alzheimer's and ALS. Denali's innovative approaches also include enzyme replacement therapy for MPS II and antibody transport vehicle programs aimed at addressing alpha-synuclein and Tau pathology. Established in 2013 and headquartered in South San Francisco, California, Denali collaborates with notable organizations including Takeda, Genentech, and the Michael J. Fox Foundation to leverage research and development in the field of neurodegeneration. The company aims to translate scientific insights into effective treatments, contributing to the ongoing effort to combat these debilitating conditions.

Homology Medicines, Inc., established in 2015 and headquartered in Bedford, Massachusetts, is a biotechnology company focused on developing genetic medicines for patients with rare genetic diseases. The company's proprietary platform employs human hematopoietic stem cell-derived adeno-associated virus vectors (AAVHSCs) to deliver genetic therapies or nuclease-free gene editing treatments in vivo, targeting various disease-relevant tissues such as the liver, central nervous system, and eye. Homology Medicines has two lead product candidates: HMI-102, currently in a Phase 1/2 clinical trial for treating phenylketonuria (PKU) in adults, and HMI-103, intended for PKU treatment in pediatric patients. Additionally, the company is developing HMI-202 to treat metachromatic leukodystrophy. Homology Medicines aims to cure the underlying causes of these diseases by leveraging its robust intellectual property portfolio and experienced management team with a proven track record in rare disease therapeutics.

Codiak BioSciences is a clinical-stage biopharmaceutical company dedicated to developing exosome-based therapeutics, a novel class of medicines with the potential to address various diseases with significant unmet medical needs. The company employs its proprietary engEx Platform, which allows for the engineering and manufacturing of exosomes, leveraging their natural role as intercellular messengers. Codiak's pipeline includes product candidates such as exoSTING and exoIL-12, targeting diverse therapeutic areas including oncology, neuro-oncology, neurology, neuromuscular diseases, and infectious diseases. Additionally, the company collaborates with the Ragon Institute to explore the potential of its exoVACC platform for vaccines against SARS-CoV-2 and HIV. Founded in 2015 and headquartered in Cambridge, Massachusetts, Codiak aims to transform therapeutic approaches by harnessing the unique properties of exosomes.

Codiak BioSciences is a clinical-stage biopharmaceutical company dedicated to developing exosome-based therapeutics, a novel class of medicines with the potential to address various diseases with significant unmet medical needs. The company employs its proprietary engEx Platform, which allows for the engineering and manufacturing of exosomes, leveraging their natural role as intercellular messengers. Codiak's pipeline includes product candidates such as exoSTING and exoIL-12, targeting diverse therapeutic areas including oncology, neuro-oncology, neurology, neuromuscular diseases, and infectious diseases. Additionally, the company collaborates with the Ragon Institute to explore the potential of its exoVACC platform for vaccines against SARS-CoV-2 and HIV. Founded in 2015 and headquartered in Cambridge, Massachusetts, Codiak aims to transform therapeutic approaches by harnessing the unique properties of exosomes.

AgBiome, LLC is a biotechnology company based in Durham, North Carolina, that focuses on developing biological products to address significant challenges in agriculture, particularly soil-borne diseases affecting greenhouse and major row crops. Utilizing advanced genomics and screening technologies, AgBiome identifies plant-associated microbes that can enhance plant health, improve pest resistance, and increase crop yields. The company operates a state-of-the-art laboratory and greenhouse facility and collaborates with prominent agricultural firms to expedite its research and product development. AgBiome's offerings include fungicides that protect crops from various diseases and a platform for capturing and screening diverse microbes for agricultural applications. Established in 2012, AgBiome aims to provide sustainable solutions that support global food production and address critical agricultural issues such as insect and nematode control.

Arivale Inc. is a wellness service provider that focuses on helping individuals optimize their health and prevent disease through a scientific approach. Founded in 2014 and headquartered in Seattle, Washington, the company analyzes various aspects of individual health, including genetics, blood markers, the gut microbiome, and lifestyle factors. By integrating this data, Arivale delivers tailored recommendations and personalized coaching to empower individuals in making informed decisions about their wellness. This comprehensive approach not only aids members in understanding their unique health profiles but also contributes to a growing dataset that supports medical research aimed at enhancing health outcomes.

Denali Therapeutics is a biopharmaceutical company dedicated to discovering and developing therapies for neurodegenerative diseases such as Alzheimer's, Parkinson's disease, and amyotrophic lateral sclerosis (ALS). The company is advancing several therapeutic candidates, including LRRK2 inhibitors like DNL201 and DNL151 for Parkinson's disease, and DNL747, a RIPK1 inhibitor targeting Alzheimer's and ALS. Denali's innovative approaches also include enzyme replacement therapy for MPS II and antibody transport vehicle programs aimed at addressing alpha-synuclein and Tau pathology. Established in 2013 and headquartered in South San Francisco, California, Denali collaborates with notable organizations including Takeda, Genentech, and the Michael J. Fox Foundation to leverage research and development in the field of neurodegeneration. The company aims to translate scientific insights into effective treatments, contributing to the ongoing effort to combat these debilitating conditions.

Kura Oncology is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing targeted therapies for cancer treatment. The company’s primary product candidate, Tipifarnib, is an orally available farnesyl transferase inhibitor currently undergoing Phase II clinical trials for solid tumors, peripheral T-cell lymphomas, and various hematologic malignancies. In addition to Tipifarnib, Kura is advancing other small molecule candidates, including KO-947, which targets dysregulated extracellular signal-related kinases, and KO-539, aimed at inhibiting the menin-mixed lineage leukemia protein interaction. Kura Oncology emphasizes precision medicine, leveraging insights from cancer genomics to create targeted treatments for patients with specific genetic profiles, addressing significant unmet medical needs across various cancer types, including lung, colorectal, thyroid, pancreatic cancers, and blood cancers such as lymphoma and leukemia. The company was founded in 2014 and operates primarily within the United States.

AgBiome, LLC is a biotechnology company based in Durham, North Carolina, that focuses on developing biological products to address significant challenges in agriculture, particularly soil-borne diseases affecting greenhouse and major row crops. Utilizing advanced genomics and screening technologies, AgBiome identifies plant-associated microbes that can enhance plant health, improve pest resistance, and increase crop yields. The company operates a state-of-the-art laboratory and greenhouse facility and collaborates with prominent agricultural firms to expedite its research and product development. AgBiome's offerings include fungicides that protect crops from various diseases and a platform for capturing and screening diverse microbes for agricultural applications. Established in 2012, AgBiome aims to provide sustainable solutions that support global food production and address critical agricultural issues such as insect and nematode control.

Syros Pharmaceuticals, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, that specializes in developing innovative treatments for cancer and monogenic diseases through gene control medicines. The company is advancing its lead product candidates, including SY-1425, a selective retinoic acid receptor alpha agonist currently in Phase II clinical trials for specific patient populations with acute myeloid leukemia and myelodysplastic syndrome, and SY-5609, a cyclin-dependent kinase 7 inhibitor under investigation in a Phase I clinical trial for advanced solid tumors. Syros is also engaged in collaborative research, including a partnership with Incyte Corporation aimed at identifying therapeutic targets for myeloproliferative neoplasms and a licensing agreement with TMRC Co. Ltd. for the development of tamibarotene. With a focus on mapping gene regulatory circuits, Syros leverages its proprietary platform and expertise to address significant unmet medical needs in oncology. Founded in 2011, the company aims to establish new standards of care for patients with hematologic malignancies.

WuXi NextCODE operates as a clinical diagnostics company specializing in sequence-based genomics. The firm provides a platform that assists physicians in obtaining critical clinical insights, enabling rapid and accurate diagnoses for patients. Its services include genome interpretation, data analysis, and data mining, along with security and data protection measures. The company also offers custom integration services and both clinical-grade and non-clinical-grade sequencing. With technology developed over 16 years at deCODE genetics, WuXi NextCODE aims to facilitate the integration of genomic data into patient care and diagnosis. Based in Cambridge, Massachusetts, the company was acquired by WuXi AppTec in 2015 and has since focused on addressing the challenges of genome interpretation and big data in healthcare.

Genuity Science is a company that specializes in clinco-omics data analysis solutions for researchers in the fields of central nervous system, cardiometabolic, and inflammatory diseases. The company provides a comprehensive global genomics platform that facilitates the study of biological data insights, offering services that include study design, genomic sequencing, data storage, interpretation, secondary analysis, and scalable analytics. By leveraging the human genome, Genuity Science aims to empower organizations to enhance patient health through advanced genomic insights and analysis.

Boreal Genomics Inc. is a biotechnology company that focuses on the development and commercialization of technologies for blood-based detection and monitoring of circulating tumor DNA. Founded in 2007 and headquartered in Los Altos, California, with an additional office in Vancouver, Canada, the company offers products like OnTarget, which allows for the sensitive detection and quantification of tumor mutations in plasma or tissue. Boreal's platform is designed to enable healthcare professionals to perform accurate genomic profiling and monitor tumor evolution from cell-free DNA in plasma, thereby improving cancer patient care. The OnTarget assay, available as a research-use service, reveals tumor mutations that may be undetectable by other methods, assisting in therapy selection, enhancing clinical trial efficiency, and expediting drug development. Additionally, Boreal provides DNA enrichment and library construction solutions tailored for high accuracy sequencing in liquid biopsy applications.

AgBiome, LLC is a biotechnology company based in Durham, North Carolina, that focuses on developing biological products to address significant challenges in agriculture, particularly soil-borne diseases affecting greenhouse and major row crops. Utilizing advanced genomics and screening technologies, AgBiome identifies plant-associated microbes that can enhance plant health, improve pest resistance, and increase crop yields. The company operates a state-of-the-art laboratory and greenhouse facility and collaborates with prominent agricultural firms to expedite its research and product development. AgBiome's offerings include fungicides that protect crops from various diseases and a platform for capturing and screening diverse microbes for agricultural applications. Established in 2012, AgBiome aims to provide sustainable solutions that support global food production and address critical agricultural issues such as insect and nematode control.

Syros Pharmaceuticals, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, that specializes in developing innovative treatments for cancer and monogenic diseases through gene control medicines. The company is advancing its lead product candidates, including SY-1425, a selective retinoic acid receptor alpha agonist currently in Phase II clinical trials for specific patient populations with acute myeloid leukemia and myelodysplastic syndrome, and SY-5609, a cyclin-dependent kinase 7 inhibitor under investigation in a Phase I clinical trial for advanced solid tumors. Syros is also engaged in collaborative research, including a partnership with Incyte Corporation aimed at identifying therapeutic targets for myeloproliferative neoplasms and a licensing agreement with TMRC Co. Ltd. for the development of tamibarotene. With a focus on mapping gene regulatory circuits, Syros leverages its proprietary platform and expertise to address significant unmet medical needs in oncology. Founded in 2011, the company aims to establish new standards of care for patients with hematologic malignancies.

Bluebird bio, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on researching, developing, and commercializing gene therapies for severe genetic diseases and cancer. The company's gene therapy programs include LentiGlobin, aimed at treating β-thalassemia and sickle cell disease, and Lenti-D for cerebral adrenoleukodystrophy. In oncology, bluebird bio is developing chimeric antigen receptor T (CAR T) cell therapies, specifically bb2121 and bb21217, for multiple myeloma. The company has formed strategic collaborations with several organizations, including Bristol-Myers Squibb and Regeneron Pharmaceuticals, to advance gene therapies in oncology and immune cell therapies. Additionally, bluebird bio collaborates with various partners to explore T cell receptor product candidates and in vivo genome editing treatments for genetic disorders. Established in 1992 and originally known as Genetix Pharmaceuticals, the company transitioned to its current name in 2010.

Groove Biopharma focuses on the generation of novel microRNA (miRNA) therapeutics with improved properties, including higher potency and enhanced pharmacodynamic activity. Endogenous microRNAs (miRNAs) are involved in extensive regulatory networks for many target genes and pathways. Groove Biopharma’s core technology addresses a new avenue of nucleotide therapeutic drug discovery via modulation of cellular miRNA. Using exclusive technology, Groove Biopharma is generating a series of lead candidates with the potential to be best-in-class therapeutics. By incorporating proprietary structural modifications into miRNA therapeutics, the Groove Biopharma technology platform presents promising potential for treating a wide range of diseases, including cancer, fibrosis, and infectious disease.

Agios Pharmaceuticals is a biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of medicines targeting cellular metabolism and related areas, including hematologic malignancies, solid tumors, and rare genetic diseases. The company offers TIBSOVO, an oral targeted inhibitor for treating relapsed or refractory acute myeloid leukemia (AML) in adult patients, and IDHIFA, which is also aimed at AML patients with specific mutations. Agios is advancing several drug candidates through various stages of clinical trials, including TIBSOVO for frontline AML and cholangiocarcinoma, mitapivat for pyruvate kinase deficiency and thalassemia, and vorasidenib for solid tumors. The company emphasizes a precision medicine approach, focusing on genetically or biomarker-defined patient populations to enhance the potential for early proof of concept and accelerated approval. Agios Pharmaceuticals was established in 2007 and has evolved from its original name, Cancer Metabolism Therapeutics, to its current identity.

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing programmed cellular immunotherapies for cancer and immune disorders. The company specializes in NK- and T-cell immuno-oncology programs, with a diverse pipeline that includes candidates such as FT516 and FT596 for treating various hematologic malignancies, FT538 for acute myeloid leukemia and multiple myeloma, and FT500 for advanced solid tumors. Fate Therapeutics employs advanced techniques involving induced pluripotent stem cells (iPSCs) to create engineered product candidates, which are designed to be off-the-shelf solutions. The company has established strategic collaborations with notable partners, including Ono Pharmaceutical Co. Ltd. and Janssen Biotech, to enhance its research and development capabilities. Founded in 2007, Fate Therapeutics aims to leverage cutting-edge science to create innovative therapies that restore health by modulating the properties of stem cells.

Bluebird bio, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on researching, developing, and commercializing gene therapies for severe genetic diseases and cancer. The company's gene therapy programs include LentiGlobin, aimed at treating β-thalassemia and sickle cell disease, and Lenti-D for cerebral adrenoleukodystrophy. In oncology, bluebird bio is developing chimeric antigen receptor T (CAR T) cell therapies, specifically bb2121 and bb21217, for multiple myeloma. The company has formed strategic collaborations with several organizations, including Bristol-Myers Squibb and Regeneron Pharmaceuticals, to advance gene therapies in oncology and immune cell therapies. Additionally, bluebird bio collaborates with various partners to explore T cell receptor product candidates and in vivo genome editing treatments for genetic disorders. Established in 1992 and originally known as Genetix Pharmaceuticals, the company transitioned to its current name in 2010.

Groove Biopharma focuses on the generation of novel microRNA (miRNA) therapeutics with improved properties, including higher potency and enhanced pharmacodynamic activity. Endogenous microRNAs (miRNAs) are involved in extensive regulatory networks for many target genes and pathways. Groove Biopharma’s core technology addresses a new avenue of nucleotide therapeutic drug discovery via modulation of cellular miRNA. Using exclusive technology, Groove Biopharma is generating a series of lead candidates with the potential to be best-in-class therapeutics. By incorporating proprietary structural modifications into miRNA therapeutics, the Groove Biopharma technology platform presents promising potential for treating a wide range of diseases, including cancer, fibrosis, and infectious disease.

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing programmed cellular immunotherapies for cancer and immune disorders. The company specializes in NK- and T-cell immuno-oncology programs, with a diverse pipeline that includes candidates such as FT516 and FT596 for treating various hematologic malignancies, FT538 for acute myeloid leukemia and multiple myeloma, and FT500 for advanced solid tumors. Fate Therapeutics employs advanced techniques involving induced pluripotent stem cells (iPSCs) to create engineered product candidates, which are designed to be off-the-shelf solutions. The company has established strategic collaborations with notable partners, including Ono Pharmaceutical Co. Ltd. and Janssen Biotech, to enhance its research and development capabilities. Founded in 2007, Fate Therapeutics aims to leverage cutting-edge science to create innovative therapies that restore health by modulating the properties of stem cells.

Elixir Pharmaceuticals is a pharmaceutical company focused on the discovery, development and commercialization of novel pharmaceuticals for the treatment of metabolic diseases such as diabetes and obesity. The Company's scientific founders identified that interactions between specific genes and enzymes can slow the aging process, and they are developing compounds that stimulate these interactions and will be used to treat a range of diseases of aging, including metabolic disease.

Agios Pharmaceuticals is a biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of medicines targeting cellular metabolism and related areas, including hematologic malignancies, solid tumors, and rare genetic diseases. The company offers TIBSOVO, an oral targeted inhibitor for treating relapsed or refractory acute myeloid leukemia (AML) in adult patients, and IDHIFA, which is also aimed at AML patients with specific mutations. Agios is advancing several drug candidates through various stages of clinical trials, including TIBSOVO for frontline AML and cholangiocarcinoma, mitapivat for pyruvate kinase deficiency and thalassemia, and vorasidenib for solid tumors. The company emphasizes a precision medicine approach, focusing on genetically or biomarker-defined patient populations to enhance the potential for early proof of concept and accelerated approval. Agios Pharmaceuticals was established in 2007 and has evolved from its original name, Cancer Metabolism Therapeutics, to its current identity.

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing programmed cellular immunotherapies for cancer and immune disorders. The company specializes in NK- and T-cell immuno-oncology programs, with a diverse pipeline that includes candidates such as FT516 and FT596 for treating various hematologic malignancies, FT538 for acute myeloid leukemia and multiple myeloma, and FT500 for advanced solid tumors. Fate Therapeutics employs advanced techniques involving induced pluripotent stem cells (iPSCs) to create engineered product candidates, which are designed to be off-the-shelf solutions. The company has established strategic collaborations with notable partners, including Ono Pharmaceutical Co. Ltd. and Janssen Biotech, to enhance its research and development capabilities. Founded in 2007, Fate Therapeutics aims to leverage cutting-edge science to create innovative therapies that restore health by modulating the properties of stem cells.

Elixir Pharmaceuticals is a pharmaceutical company focused on the discovery, development and commercialization of novel pharmaceuticals for the treatment of metabolic diseases such as diabetes and obesity. The Company's scientific founders identified that interactions between specific genes and enzymes can slow the aging process, and they are developing compounds that stimulate these interactions and will be used to treat a range of diseases of aging, including metabolic disease.

Elixir Pharmaceuticals is a pharmaceutical company focused on the discovery, development and commercialization of novel pharmaceuticals for the treatment of metabolic diseases such as diabetes and obesity. The Company's scientific founders identified that interactions between specific genes and enzymes can slow the aging process, and they are developing compounds that stimulate these interactions and will be used to treat a range of diseases of aging, including metabolic disease.

Alnylam Pharmaceuticals is a biopharmaceutical company specializing in the discovery, development, and commercialization of RNA interference (RNAi) therapeutics. The company focuses on addressing rare genetic diseases, cardio-metabolic conditions, hepatic infectious diseases, and central nervous system/ocular disorders. Its marketed products include ONPATTRO, a treatment for hereditary transthyretin-mediated amyloidosis, and GIVLAARI, which targets acute hepatic porphyria. Alnylam’s pipeline includes investigational therapies such as givosiran for acute hepatic porphyria, lumasiran for primary hyperoxaluria type 1, and vutrisiran for transthyretin amyloidosis. The company has established strategic alliances with notable partners like Sanofi Genzyme and Regeneron Pharmaceuticals, and it collaborates with Vir Biotechnology on RNAi therapeutics for coronavirus infections. Founded in 2002 and headquartered in Cambridge, Massachusetts, Alnylam Pharmaceuticals is at the forefront of transforming RNAi science into innovative medicines to improve patient outcomes.

Illumina is a leading technology company specializing in the analysis of genetic material, focusing on life science and clinical laboratory applications. The company generates the majority of its revenue from sequencing instruments, consumables, and related services. Illumina's high-throughput technology facilitates whole genome sequencing for humans and other large organisms, while its lower throughput tools cater to applications requiring smaller data sets, such as viral and cancer tumor screening. In addition, Illumina offers microarrays for lower-cost, targeted genetic screening, primarily serving consumer and agricultural sectors. By providing innovative and flexible solutions, Illumina plays a crucial role in advancing personalized medicine and supports disease research, drug development, and the creation of molecular tests in clinical settings.